Impact of Blood Type, Functional Polymorphism (T-1676C) of the COX-1 Gene Promoter and Clinical Factors on the Development of Peptic Ulcer during Cardiovascular Prophylaxis with Low-Dose Aspirin

Table 1

Clinical characteristics of aspirin users with and without peptic ulcer.

	Gastritis/normal	Peptic ulcer	value
Age			0.001
Sex			0.501
Female	40 (36.7%)	31 (27.9%)
Male	69 (63.3%)	80 (72.1%)
Cigarette smoking	13 (11.9%)	19 (17.1%)	0.275
Heavy drinker	7 (6.4%)	9 (8.1%)	0.630
Coffee consumption	22 (20.2%)	11 (9.9%)	0.033
Tea consumption	36 (33.0%)	27 (24.3%)	0.153
History of peptic ulcer	4 (3.7%)	56 (50.5%)	0.000
Dual antiplatelet therapy	10 (9.2%)	10 (9.0%)	0.966
Coumadin use	1 (0.9%)	3 (2.7%)	0.622
Nonaspirin NSAID use	7 (6.4%)	18 (16.2%)	0.022
Steroid use	2 (1.8%)	2 (1.8%)	1.000
H. pylori infection	52 (47.7%)	29 (26.1%)	0.005

denotes .